Suntinorexton
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C23H28F2N2O4S |
| Molar mass | 466.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Suntinorexton (INN; developmental code name TAK-861) is an experimental orexin receptor agonist.[1][2] It acts as a selective agonist of the orexin OX2 receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.[3] Suntinorexton has superseded danavorexton (TAK-925) and firazorexton (TAK-994) as a clinical drug candidate owing to toxicity of these agents.[1] The drug has reached phase 3 clinical trials as of 2024.[1][4] It is orally active and centrally penetrant.[1]
See also
[edit]References
[edit]- ^ a b c d e Konofal, Eric (2024). "From past to future: 50 years of pharmacological interventions to treat narcolepsy". Pharmacology Biochemistry and Behavior. 241: 173804. doi:10.1016/j.pbb.2024.173804.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (1): 93–269. 2020.
Proposed INN: List 123
- ^ WO application 2019027058, Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, Takeuchi K, Ito Y, Tokunaga N, Sugimoto T, Miyazaki T, Oda T, Hoashi Y, Hattori Y, Imamura K, "Heterocyclic compound and use therof", published 2019-02-07, assigned to Takeda Pharmaceutical Company.
- ^ "TAK 861". AdisInsight. 12 July 2024. Retrieved 30 July 2024.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |